Search Results for "diagnosis"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Lumasiran: ILLUMINATE-A Study Overview
Standard response letter on the lumasiran phase 3 clinical study ILLUMINATE-A, a study evaluating the efficacy and safety of lumasiran in adults and children who are 6 years of age or older with PH1.
Standard response letter on the lumasiran phase 3 clinical study ILLUMINATE-A, a study evaluating the efficacy and safety of lumasiran in adults and children who are 6 years of age or older with PH1.
